What are examples of cGMP violations that affect insurance?

Five categories of cGMP violation recur in FDA Warning Letters and produce material insurance consequences. Data integrity failures (incomplete records, backdated logs, deleted audit trails) are now the most frequently cited cGMP issue and produce the broadest products liability exposure because they undermine the regulatory record that establishes product quality.

Environmental monitoring deficiencies (failure to detect microbial or particulate contamination in sterile manufacturing areas) drive products liability claims for sterile injectable and ophthalmic products. USP <797> non-compliance in sterile compounding facilities produces both regulatory enforcement and product liability claims simultaneously.

Inadequate Corrective and Preventive Action (CAPA) programs - where deviations are documented but root cause analysis and systemic correction are weak - create a pattern that underwriters identify as a deteriorating risk. Renewal pricing typically reflects the trend.

Microbial contamination events (Burkholderia cepacia in oral solutions, gram-negative organisms in injectables) produce both first-party recall costs and third-party bodily injury claims, often simultaneously, exhausting both products liability and recall limits.

Validation lapses on critical equipment, cleaning processes, or analytical methods undermine the regulatory record for batches manufactured during the lapse window, creating retrospective product liability for previously distributed product.